Home › Funds › Merck & Co., Inc. › STRO
Merck & Co., Inc. position in STRO
SUTRO BIOPHARMA INC · Health Care
Merck & Co., Inc. reported holding 272,351 shares of STRO (SUTRO BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.53% of its reported portfolio and ranking #8 among its reported holdings. Merck & Co., Inc. has disclosed STRO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s STRO position evolved
Merck & Co., Inc. first disclosed a stake in STRO in Q4 2024 at 2,723,509 shares (US$5.0M). The position peaked in Q2 2026 at 272,351 shares, worth US$9.0M. Across 8 filings, Merck & Co., Inc. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 272,351 shares valued at US$4.4M. Notable position changes include a 90% trim in Q4 2025 (shares rose 115% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.72M | $5.01M | New |
| Q1 2025 | 2.72M | $1.77M | Hold |
| Q2 2025 | 2.72M | $1.94M | Hold |
| Q3 2025 | 2.72M | $2.37M | Hold |
| Q4 2025 | 272.35K | $3.15M | Reduce |
| Q1 2026 | 272.35K | $6.78M | Hold |
| Q2 2026 | 272.35K | $9.04M | Hold |
| Q3 2026 | 272.35K | $4.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STRO and 13F data
STRO (SUTRO BIOPHARMA INC) is a Health Care company. 37 other funds we track also report a position in STRO — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$43.3M), BVF INC/IL (US$41.6M), Samsara BioCapital, LLC (US$35.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STRO
- PERCEPTIVE ADVISORS LLC 1.30M sh · $43.32M · Q2 2026
- BVF INC/IL 1.25M sh · $41.56M · Q2 2026
- Samsara BioCapital, LLC 1.06M sh · $35.29M · Q2 2026
- Kynam Capital Management, LP 872.56K sh · $28.97M · Q2 2026
- Affinity Asset Advisors, LLC 1.15M sh · $18.57M · Q3 2026
- Velan Capital Investment Management LP 512.16K sh · $17.00M · Q2 2026
- ADAR1 Capital Management, LLC 404.01K sh · $13.41M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 270.25K sh · $8.97M · Q2 2026
- KVP Capital Advisors, LP 226.57K sh · $7.52M · Q2 2026
- Seven Fleet Capital Management LP 159.12K sh · $3.79M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held STRO?
Merck & Co., Inc. has disclosed STRO holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in STRO?
As of Q3 2026, Merck & Co., Inc. holds 272.35K shares of STRO (SUTRO BIOPHARMA INC), valued at $4.39M, representing 0.53% of its reported portfolio and ranking #8.
Has Merck & Co., Inc. been buying or selling STRO?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in STRO. The position peaked in Q2 2026 at 272.35K shares.
Which other funds hold STRO?
Other major institutional holders of STRO include PERCEPTIVE ADVISORS LLC, BVF INC/IL, Samsara BioCapital, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.